Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients w...
Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )
19 Apr 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )
16 Apr 2021
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )
16 Apr 2021
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...
Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )
16 Apr 2021
Clinical validation of a targeted methylation-based multi-cancer early detection...
Dr Eric Klein - Cleveland Clinic, Cleveland, USA
Clinical validation of a targeted methylation-based multi-cancer early detection test ( Dr Eric Klein - Cleveland Clinic, Cleveland, USA )
13 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers ( Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA )
13 Apr 2021
High-quality neoantigens are immunoedited in long-term survivors of pancreatic c...
Prof Marta Luksza - Tisch Cancer Institute, New York, USA
High-quality neoantigens are immunoedited in long-term survivors of pancreatic cancer ( Prof Marta Luksza - Tisch Cancer Institute, New York, USA )
12 Apr 2021
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407 ( Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada )
9 Apr 2021
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD  II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )
9 Apr 2021
IMpower133: Exploratory analysis of maintenance therapy in patients with exten...
Prof Martin Reck and Dr Antonio Passaro
IMpower133: Exploratory analysis of  maintenance therapy in patients with  extensive-stage small-cell lung cancer ( Prof Martin Reck and Dr Antonio Passaro )
1 Apr 2021
Highlights from AORTIC Cancer Genomics Conference 2021
Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, ...
Highlights from AORTIC Cancer Genomics Conference 2021 ( Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, Accra, Ghana )
30 Mar 2021
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Prof Ales Ryska - Charles University, Prague, Czech Republic
Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )
29 Mar 2021